Wei Zhang

List of Publications by Citations

44 papers	**9,400** citations
22 h-index	**45** g-index
45 ext. papers	**12,765** ext. citations
11.6 avg, IF	**4.35** L-index

#	Paper	IF	Citations
44	The somatic genomic landscape of glioblastoma. *Cell*, **2013**, 155, 462-77	56.2	2900
43	Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. *New England Journal of Medicine*, **2015**, 372, 2481-98	59.2	1828
42	The Immune Landscape of Cancer. *Immunity*, **2018**, 48, 812-830.e14	32.3	1754
41	Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. *Cell*, **2016**, 164, 550-63	56.2	1140
40	CGCG clinical practice guidelines for the management of adult diffuse gliomas. *Cancer Letters*, **2016**, 375, 263-273	9.9	253
39	RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas. *Genome Research*, **2014**, 24, 1765-73	9.7	237
38	Molecular classification of gliomas based on whole genome gene expression: a systematic report of 225 samples from the Chinese Glioma Cooperative Group. *Neuro-Oncology*, **2012**, 14, 1432-40	1	133
37	Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor. *Cell*, **2018**, 175, 1665-1678.e18	56.2	125
36	Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma. *OncoImmunology*, **2016**, 5, e1196310	7.2	116
35	Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers. *Cell Reports*, **2018**, 23, 255-269.e4	10.6	112
34	Chinese Glioma Genome Atlas (CGGA): A Comprehensive Resource with Functional Genomic Data from Chinese Glioma Patients. *Genomics, Proteomics and Bioinformatics*, **2021**, 19, 1-12	6.5	103
33	Correlation of IDH1 mutation with clinicopathologic factors and prognosis in primary glioblastoma: a report of 118 patients from China. *PLoS ONE*, **2012**, 7, e30339	3.7	99
32	Molecular and clinical characterization of TIM-3 in glioma through 1,024 samples. *OncoImmunology*, **2017**, 6, e1328339	7.2	74
31	Whole-genome microRNA expression profiling identifies a 5-microRNA signature as a prognostic biomarker in Chinese patients with primary glioblastoma multiforme. *Cancer*, **2013**, 119, 814-24	6.4	74
30	A glioma classification scheme based on coexpression modules of EGFR and PDGFRA. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 3538-43	11.5	70
29	Clinical practice guidelines for the management of adult diffuse gliomas. *Cancer Letters*, **2021**, 499, 60-72	9.9	61
28	Genome-wide DNA methylation profiling identifies ALDH1A3 promoter methylation as a prognostic predictor in G-CIMP- primary glioblastoma. *Cancer Letters*, **2013**, 328, 120-5	9.9	53

#	Reference	IF	Citations
27	Genetic, epigenetic, and molecular landscapes of multifocal and multicentric glioblastoma. *Acta Neuropathologica*, **2015**, 130, 587-97	14.3	46
26	Identification of high risk anaplastic gliomas by a diagnostic and prognostic signature derived from mRNA expression profiling. *Oncotarget*, **2015**, 6, 36643-51	3.3	32
25	Multidimensional analysis of gene expression reveals TGFB1I1-induced EMT contributes to malignant progression of astrocytomas. *Oncotarget*, **2014**, 5, 12593-606	3.3	31
24	ALDH1A3 induces mesenchymal differentiation and serves as a predictor for survival in glioblastoma. *Cell Death and Disease*, **2018**, 9, 1190	9.8	27
23	Classification of diffuse lower-grade glioma based on immunological profiling. *Molecular Oncology*, **2020**, 14, 2081-2095	7.9	24
22	Molecular subtyping reveals immune alterations in IDH wild-type lower-grade diffuse glioma. *Journal of Pathology*, **2020**, 251, 272-283	9.4	19
21	Whole-genome mRNA expression profiling identifies functional and prognostic signatures in patients with mesenchymal glioblastoma multiforme. *CNS Neuroscience and Therapeutics*, **2013**, 19, 714-20	6.8	17
20	Siglecs, Novel Immunotherapy Targets, Potentially Enhance The Effectiveness of Existing Immune Checkpoint Inhibitors in Glioma Immunotherapy. *OncoTargets and Therapy*, **2019**, 12, 10263-10273	4.4	11
19	Single-Cell RNA-Sequencing Shift in the Interaction Pattern Between Glioma Stem Cells and Immune Cells During Tumorigenesis. *Frontiers in Immunology*, **2020**, 11, 581209	8.4	10
18	Chinese Glioma Genome Atlas (CGGA): A Comprehensive Resource with Functional Genomic Data for Chinese Glioma Patients		8
17	Redox Regulator Is Associated With Tumor Immunity in Glioma. *Frontiers in Immunology*, **2020**, 11, 580934	8.4	8
16	Rapalink-1 Targets Glioblastoma Stem Cells and Acts Synergistically with Tumor Treating Fields to Reduce Resistance against Temozolomide. *Cancers*, **2020**, 12,	6.6	7
15	Postoperative standard chemoradiotherapy benefits primary glioblastoma patients of all ages. *Cancer Medicine*, **2020**, 9, 1955-1965	4.8	5
14	A computational guided, functional validation of a novel therapeutic antibody proposes Notch signaling as a clinical relevant and druggable target in glioma. *Scientific Reports*, **2020**, 10, 16218	4.9	5
13	Clinical Characterization and Immunosuppressive Regulation of CD161 (KLRB1) in Glioma through 916 Samples. *Cancer Science*, **2021**,	6.9	4
12	Carbonic Anhydrase XII is a Clinically Significant, Molecular Tumor-Subtype Specific Therapeutic Target in Glioma with the Potential to Combat Invasion of Brain Tumor Cells. *OncoTargets and Therapy*, **2021**, 14, 1707-1718	4.4	3
11	A novel methylation signature predicts radiotherapy sensitivity in glioma. *Scientific Reports*, **2020**, 10, 20406	4.9	2
10	High-sensitive clinical diagnostic method for PTPRZ1-MET and the characteristic protein structure contributing to ligand-independent MET activation. *CNS Neuroscience and Therapeutics*, **2021**, 27, 617-628	6.8	2

9	Galectin-9/TIM-3 as a Key Regulator of Immune Response in Gliomas With Chromosome 1p/19q Codeletion.. *Frontiers in Immunology*, **2021**, 12, 800928	8.4	2
8	In Vitro Validation of the Therapeutic Potential of Dendrimer-Based Nanoformulations against Tumor Stem Cells. *International Journal of Molecular Sciences*, **2022**, 23, 5691	6.3	2
7	A potentially effective drug for patients with recurrent glioma: sermorelin. *Annals of Translational Medicine*, **2021**, 9, 406	3.2	1
6	neoDL: a novel neoantigen intrinsic feature-based deep learning model identifies IDH wild-type glioblastomas with the longest survival. *BMC Bioinformatics*, **2021**, 22, 382	3.6	1
5	A novel DNA repair-related nomogram predicts survival in low-grade gliomas. *CNS Neuroscience and Therapeutics*, **2021**, 27, 186-195	6.8	1
4	Metabolic expression profiling stratifies diffuse lower-grade glioma into three distinct tumour subtypes. *British Journal of Cancer*, **2021**, 125, 255-264	8.7	0
3	Integrated analysis of the prognostic and oncogenic roles of OPN3 in human cancers.. *BMC Cancer*, **2022**, 22, 187	4.8	0
2	Development and Validation of a Novel Prognostic Model for Lower-Grade Glioma Based on Enhancer RNA-Regulated Prognostic Genes.. *Frontiers in Oncology*, **2022**, 12, 714338	5.3	0
1	Multiomics Analysis Reveals the Prognostic Non-tumor Cell Landscape in Glioblastoma Niches. *Frontiers in Genetics*, **2021**, 12, 741325	4.5	